While CA-125 and other protein-based biomarkers have demonstrated the most success detecting ovarian cancer thus far, recent studies have found that implementation of CA-125 in ovarian cancer screening protocols have not made an equivocal impact on patient survival. This evidence concerns the gene MUC16 and ovarian carcinoma.